

HB1217/313728/1

BY: Health and Government Operations Committee

AMENDMENTS TO HOUSE BILL 1217
(First Reading File Bill)

AMENDMENT NO. 1

On page 1, in the sponsor line, strike “**Kelly,**”; and in the same line, strike “**and Wilkins**” and substitute “**Wilkins, Bagnall, Bhandari, Chisholm, Cullison, Guzzone, Hill, Hutchinson, S. Johnson, Kaiser, Kerr, Kipke, R. Lewis, Lopez, Martinez, M. Morgan, Pena–Melnyk, Reilly, Rosenberg, Szeliga, Taveras, and Woods**”.

AMENDMENT NO. 2

On page 2, in line 8, strike “**THE**” and substitute “**BEGINNING JULY 1, 2025, THE**”; and in line 28, strike “**JANUARY 1, 2024**” and substitute “**JULY 1, 2025**”.

AMENDMENT NO. 3

On page 3, in line 13, after “**BIOMARKER**” insert “**, THE RESULTS OF WHICH:**

1. PROVIDE INFORMATION THAT MAY BE USED IN THE FORMULATION OF A TREATMENT OR MONITORING STRATEGY THAT INFORMS A PATIENT’S OUTCOME AND IMPACTS THE CLINICAL DECISION; AND

2. INCLUDE BOTH INFORMATION THAT IS ACTIONABLE AND SOME INFORMATION THAT CANNOT BE IMMEDIATELY USED IN THE FORMULATION OF A CLINICAL DECISION”.

AMENDMENT NO. 4

On page 4, in line 10, after “**DETERMINATION;**” insert “**OR**”; and strike beginning with “**; OR**” in line 19 down through “**CARE**” in line 26.

HB1217/313728/01 Health and Government Operations Committee
Amendments to HB 1217
Page 2 of 2

On page 5, strike in their entirety lines 8 through 21, inclusive, and substitute:

“SECTION 2. AND BE IT FURTHER ENACTED, That on or before December 1, 2024, the Maryland Department of Health shall report to the Governor and, in accordance with § 2–1257 of the State Government Article, the General Assembly on the following:

(1) the fiscal impact of the biomarkers testing coverage required under Section 1 of this Act on the Maryland Medical Assistance Program’s policy on biomarkers testing coverage for specific cancers during fiscal year 2024;

(2) any available data on use of biomarkers testing by race and ethnicity in the Program;

(3) the anticipated fiscal and access impacts of expanding the coverage required under Section 1 of this Act to the Maryland Medical Assistance Program in fiscal year 2026; and

(4) recommendations on any legislative changes to the requirements established under Section 1 of this Act relating to the Maryland Medical Assistance Program, including managed care organizations.

SECTION 3. AND BE IT FURTHER ENACTED, That on or before December 1, 2025, the Maryland Health Care Commission shall report to the Senate Finance Committee and the House Health and Government Operations Committee, in accordance with § 2–1257 of the State Government Article, on the impact of providing biomarker testing coverage required under Section 1 of this Act, including an analysis of the impact of providing access to biomarker testing to individuals based on race, gender, age, and public or private insurance.”;

in lines 22 and 25, strike “2.” and “3.”, respectively, and substitute “4.” and “5.”, respectively; and in line 22, after “That” insert “Section 1 of”.